FGF2 and peripheral arterial disease: Numerous cardiovascular clinical trials for peripheral arterial disease (PAD), heart failure, and stroke have sought to augment angiogenesis by administering growth factors that promote EC proliferation and migration (e.g. VEGF and bFGF) as a means to increase tissue perfusion and recovery17–20.